In order to enhance international visibility, the 3rd Asia Pacific Biotech Investment Forum organized by Diamond Biofund and Institute for Biotechnology and Medicine Industry, invited Larry Lin, Ph.D., Senior Vice President, Business Development & Licensing, Far East Hub from Merck & Co., Inc., Mingde Xia, Ph.D., Senior Director, New Ventures from Johnson & Johnson Co., Ltd., Michael Chen, Ph.D., Head of External Innovation China from Merck and other international heavyweight guests came to share the key point of discovering the potential business from the industrial perspective.

Through this international conference platform, the Microbio group also jointly held six heavyweight investor conferences, total capitals are more than NTD 10 billion, including MICROBIO(4128), ONENESS (4743), FOUNTAIN BIOPHARMA(4159) , Sinew Pharma, CHO Pharma, and Iridium Medical Technology. The attended companies shared the latest achievements in research and development and commercialization which successfully drawing attention from venture capital and capital market.

At the beginning of the forum, Wei-Cho Chen, Ph.D., Honorary Chairman of Institute for Biotechnology and Medicine Industry and Chih-Kung Lee, Ph.D., Minister from Ministry of Economic Affairs gave an opening speech, afterwards San-Cheng Chang Ph.D., Chairman of Institute for Biotechnology and Medicine Industry delivered a speech on "The Strength of Biotech Industry in Taiwan". San-Cheng Chang Ph.D. said that the team work was essential for Taiwan to strengthen exchanges the cooperation and expand the visibility within international community.

Diamond Biofund held Asia Pacific Biotech Investment Forum for three consecutive years, constructing international healthcare partnering platform, to promote the commercial transaction; allowing Taiwan's biotechnology industry to link the global health and medical energy and achieving a star-up enterprises, the international pharmaceutical companies and capital markets win-win situation.

The forum was packed, attracting more than three hundred domestic and foreign audiences to attend this event and also successfully made more than 50 enterprises, investors and international pharmaceutical companies had directly one-to-one partnering meeting, had a significant contribution on connecting Taiwan's biotechnology industry to international market.